This combination strategy was found to be effective in hepatocellular carcinoma, kidney cell cancer, lung cancer, and head and neck squamous cell carcinoma.18,19,20,21,22,23 In hepatocellular carcinoma, atezolizumab selectively targets PD-L1 to prevent interaction with receptors PD-1 and B7-1, thus reversing T cell suppression; bevacizumab is a monoclonal antibody that targets VEGF, inhibits angiogenesis and tumor growth, and reduces VEGF-mediated immunosuppression within the tumor and its microenvironment. This evidence concerns the gene CD274 and lung cancer.